Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant Disease

November 10th 2016

Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.

FDA Approves Blinatumomab for Pediatric Acute Lymphoblastic Leukemia

September 2nd 2016

The FDA has granted an accelerated approval to blinatumomab (Blincyto) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Soft Tissue Sarcoma: Looking Ahead

July 29th 2016

Olaratumab Efficacy in Soft-Tissue Sarcoma

July 29th 2016

Eribulin Mesylate in Soft Tissue Sarcoma

July 29th 2016

Efficacy and Toxicities with Trabectedin in Sarcomas

July 29th 2016

The Role of Trabectedin in Sarcoma Subtypes

July 29th 2016

Recent Approvals in Soft Tissue Sarcoma

July 29th 2016

Sequencing Decisions in Soft Tissue Sarcoma

July 29th 2016

Frontline Approach in Advanced Sarcomas

July 29th 2016

Chemotherapy Sensitivity in Soft Tissue Sarcoma

July 29th 2016

Local Control in Metastatic Soft Tissue Sarcoma

July 29th 2016

Goals of Therapy in Sarcoma

July 29th 2016

Challenges in Treating Soft Tissue Sarcomas in Younger Populations

July 29th 2016

Soft Tissue Sarcoma: Factors Impacting Initial Approach

July 29th 2016

When to Suspect Sarcoma

July 29th 2016

FDA Panel Endorses Early Trials of Promising Anticancer Agents in Pediatric Patients

June 29th 2016

Members of the Pediatric Subcommittee of the FDA's Oncologic Drugs Advisory Committee voiced their support for new clinical trials examining promising cancer agents in pediatric patients.

FDA Approval Sought for Blinatumomab in Pediatric Acute Lymphoblastic Leukemia

March 3rd 2016

A supplemental biologics license application has been submitted to the FDA to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL

November 5th 2015

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).

Dr. Stephen Huang on Challenges in Pediatric Thyroid Cancer

October 22nd 2015

Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.